Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Travere Therapeutics Inc. (NASDAQ: TVTX) Near the Top of Equities by Percentage Gain on 12/5 By: Investor Brand Network December 05, 2023 at 11:23 AM EST Travere Therapeutics, Inc. (NASDAQ: TVTX) is one of today’s top gainers. The company’s shares have moved -0.59% on the day to $6.76. Travere Therapeutics, Inc., a biopharmaceutical company, focuses on the identification, development, commercialization, and delivering of therapies for the treatment of rare diseases. Its marketed products include Chenodal, a synthetic oral form of chenodeoxycholic acid for the treatment of radiolucent stones in gallbladders; Cholbam, a cholic acid capsule to treat pediatric and adult patients with bile acid synthesis disorders due to single enzyme defects. So far today, approximately 1.2M shares of Travere Therapeutics, Inc. have been exchanged, as compared to an average 30-day volume of 1.23M shares. Travere Therapeutics, Inc. share prices have moved between a 52-week high of $23.18 and a 52-week low of $6.66. The stock has moved -7.53% over the past week. To learn more about Travere Therapeutics, Inc., visit the company’s website at https://www.travere.com. Receive IBN Spotlights – “Bite Size” Small, Mid and Large-Cap Technical Indicator Alerts To stay connected with our complimentary IBN Spotlights, please visit https://IBN.fm/connected About IBN IBN consists of financial brands introduced to the investment public over the course of 17+ years. With IBN, we have amassed a collective audience of millions of social media followers. These distinctive investor brands aim to fulfill the unique needs of a growing base of client-partners. IBN will continue to expand our branded network of highly influential properties, leveraging the knowledge and energy of specialized teams of experts to serve our increasingly diversified list of clients. Through our Dynamic Brand Portfolio (DBP), IBN provides: (1) access to a network of wire solutions via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible; (2) article and editorial syndication to 5,000+ news outlets; (3) Press Release Enhancement to ensure maximum impact; (4) full-scale distribution to a growing social media audience; (5) a full array of corporate communications solutions; and (6) total news coverage solutions. For more information, please visit https://www.InvestorBrandNetwork.com Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer IBNLos Angeles, Californiawww.InvestorBrandNetwork.com310.299.1717 OfficeEditor@InvestorBrandNetwork.com Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.
Travere Therapeutics Inc. (NASDAQ: TVTX) Near the Top of Equities by Percentage Gain on 12/5 By: Investor Brand Network December 05, 2023 at 11:23 AM EST Travere Therapeutics, Inc. (NASDAQ: TVTX) is one of today’s top gainers. The company’s shares have moved -0.59% on the day to $6.76. Travere Therapeutics, Inc., a biopharmaceutical company, focuses on the identification, development, commercialization, and delivering of therapies for the treatment of rare diseases. Its marketed products include Chenodal, a synthetic oral form of chenodeoxycholic acid for the treatment of radiolucent stones in gallbladders; Cholbam, a cholic acid capsule to treat pediatric and adult patients with bile acid synthesis disorders due to single enzyme defects. So far today, approximately 1.2M shares of Travere Therapeutics, Inc. have been exchanged, as compared to an average 30-day volume of 1.23M shares. Travere Therapeutics, Inc. share prices have moved between a 52-week high of $23.18 and a 52-week low of $6.66. The stock has moved -7.53% over the past week. To learn more about Travere Therapeutics, Inc., visit the company’s website at https://www.travere.com. Receive IBN Spotlights – “Bite Size” Small, Mid and Large-Cap Technical Indicator Alerts To stay connected with our complimentary IBN Spotlights, please visit https://IBN.fm/connected About IBN IBN consists of financial brands introduced to the investment public over the course of 17+ years. With IBN, we have amassed a collective audience of millions of social media followers. These distinctive investor brands aim to fulfill the unique needs of a growing base of client-partners. IBN will continue to expand our branded network of highly influential properties, leveraging the knowledge and energy of specialized teams of experts to serve our increasingly diversified list of clients. Through our Dynamic Brand Portfolio (DBP), IBN provides: (1) access to a network of wire solutions via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible; (2) article and editorial syndication to 5,000+ news outlets; (3) Press Release Enhancement to ensure maximum impact; (4) full-scale distribution to a growing social media audience; (5) a full array of corporate communications solutions; and (6) total news coverage solutions. For more information, please visit https://www.InvestorBrandNetwork.com Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer IBNLos Angeles, Californiawww.InvestorBrandNetwork.com310.299.1717 OfficeEditor@InvestorBrandNetwork.com
Travere Therapeutics, Inc. (NASDAQ: TVTX) is one of today’s top gainers. The company’s shares have moved -0.59% on the day to $6.76. Travere Therapeutics, Inc., a biopharmaceutical company, focuses on the identification, development, commercialization, and delivering of therapies for the treatment of rare diseases. Its marketed products include Chenodal, a synthetic oral form of chenodeoxycholic acid for the treatment of radiolucent stones in gallbladders; Cholbam, a cholic acid capsule to treat pediatric and adult patients with bile acid synthesis disorders due to single enzyme defects. So far today, approximately 1.2M shares of Travere Therapeutics, Inc. have been exchanged, as compared to an average 30-day volume of 1.23M shares. Travere Therapeutics, Inc. share prices have moved between a 52-week high of $23.18 and a 52-week low of $6.66. The stock has moved -7.53% over the past week. To learn more about Travere Therapeutics, Inc., visit the company’s website at https://www.travere.com. Receive IBN Spotlights – “Bite Size” Small, Mid and Large-Cap Technical Indicator Alerts To stay connected with our complimentary IBN Spotlights, please visit https://IBN.fm/connected About IBN IBN consists of financial brands introduced to the investment public over the course of 17+ years. With IBN, we have amassed a collective audience of millions of social media followers. These distinctive investor brands aim to fulfill the unique needs of a growing base of client-partners. IBN will continue to expand our branded network of highly influential properties, leveraging the knowledge and energy of specialized teams of experts to serve our increasingly diversified list of clients. Through our Dynamic Brand Portfolio (DBP), IBN provides: (1) access to a network of wire solutions via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible; (2) article and editorial syndication to 5,000+ news outlets; (3) Press Release Enhancement to ensure maximum impact; (4) full-scale distribution to a growing social media audience; (5) a full array of corporate communications solutions; and (6) total news coverage solutions. For more information, please visit https://www.InvestorBrandNetwork.com Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer IBNLos Angeles, Californiawww.InvestorBrandNetwork.com310.299.1717 OfficeEditor@InvestorBrandNetwork.com